At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 86 enrolled
Drug / intervention
Low dose tenecteplase +1 moredrug
Likely dose
Low dose tenecteplase 0.25 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Chinese Acute Tissue-based Imaging Selection for Lysis in Stroke: a Prospective, Multicentre, Randomized, Open-label, Rater-blinded, Randomized Trial
In Brief
A Phase 2 clinical trial evaluating Low dose tenecteplase and High dose tenecteplase for Stroke. Completed, enrolled 86 participants across 1 site.
Detailed Summary
To select the best dosage of tenecteplase for acute ischemic stroke patients (onset time 4.5-24h) of large vessel occlusion using early combined CT/MR imaging outcomes
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke
CountriesChina
CollaboratorsThe First Affiliated Hospital of Shanxi Medical University, Ningbo No. 1 Hospital, Zhejiang Province People's Hospital, Shanghai 5th People's Hospital, Shanghai 10th People's Hospital, Shanghai 6th People's Hospital, The Second Affiliated Hospital of Chongqing Medical University, The Second People's Hospital of Huai'an, Pu'er City People's Hospital, ShuGuang Hospital, Shanghai East Hospital, First People's Hospital of Shenyang
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartDec 2019
Primary CompletionDec 2021
TodayJul 2026
First PostedSep 11, 2019
Enrollment StartDec 9, 2019
Primary CompletionDec 31, 2021
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 6.8 years ago
Interventions
Low dose tenecteplasedrug
Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
High dose tenecteplasedrug
Intravenous (IV) tenecteplase 0.32 mg/kg (single bolus; maximum dose 32 mg)